WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 15-July-2017 (data as of 11-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 93'8201 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 61'4721 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 5'255  5'200  5'140  5'077  5'012  4'499  4'247  4'086 
Births 62  62  61  60  60  58  58  50 
Surviving infants 62  62  61  60  60  58  58  50 
Pop. less than 5 years 306  309  309  311  313  302  280  261 
Pop. less than 15 years 937  934  929  927  926  899  804  906 
Female 15-49 years 1'208  1'201  1'191  1'178  1'163  1'068  1'055  926 

Number of reported cases

(Click for retrospective incidence data for Norway)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  14  95  1'322 
Mumps
ChartChart
  83  181  18  35  30 
Pertussis
ChartChart
  2'207  1'902  3'032  2'608  4'231  3'417  208  2'003 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Norway)
Vaccine year result method % card seen                                                
BCG         
DTP1          99*  99*  99  99  99*  99 
DTP3          96  95  93  94  95  90  86 
DTP4          94  93  91 
IPV1          99*  99*  99 
HepB_BD         
HepB3         
Hib3          96  95  94  95  95  93 
JapEnc         
MCV1          96  95  94  93  94  88  87 
MCV2          91  91  92  91  91  90 
MenA         
PCV1          99  99  99  99  99 
PCV2          98  98  97  97  97 
PCV3          94  93  91  93  93 
Pol3          96  95  93  94  95  91  84 
Rota1         
RotaC         
RCV1          96  95  94  93  94 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Norway)
DTP1
  99  99  99  99  99  99  95 
DTP3
  96  95  93  94  95  90  86 
HepB3
 
HepB_BD
 
Hib3
  96  95  94  95  95  93 
MCV1
  96  95  94  93  94  88  87 
MCV2
  91  91  92  91  91  90 
PCV3
  94  93  91  93  93 
Pol3
  96  95  93  94  95  91  84 
RCV1
  96  95  94  93  94  88  87 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 19  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 6 weeks; Yes Defined risk
DTaPHibHepIPV 3, 5, 12 months; Yes from February 2017
DTaPHibIPV 3, 5, 12 months; Yes
DTaPIPV 7 years; Yes
HepB_Adult 1st contact, +1, +6 months; Yes defined risk groups
HepB_Pediatric birth; 1, 6 months; Yes defined risk groups
HPV 12 years (x3); Yes girls
Influenza_Adult >= 65 years; Yes pregnant women, health care workers, people suffering from chronic illness and other risk groups
Influenza_Pediatric Yes Children with chronic diseases
MMR 15 months; 11 years; Yes
Pneumo_conj 3, 5, 12 months; Yes
Rotavirus 6 weeks; 3 months; Yes
TdaPIPV 15 years; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number NA             

System performance

Total Nº districts in country number 19  19  19  19  19  19  19 
Nº districts with DTP3 coverage >=80% number 19  19  19  19  19  19  19 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 16  18 
% of districts with MCV1 coverage >=95% From 0 to 100% 84  95  47  11  42  37 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100       

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.